Consumer healthcare company Futura Medical plc (AIM: FUM) reported on Monday that it has recorded positive results from a Home User Test evaluating its marketed Eroxon product alongside a prototype formulation, Eroxon Intense, reinforcing efficacy and supporting further regulatory progress.

The four-week study, involving 223 UK-based male participants aged 18-59, most of whom had mild to moderate erectile dysfunction, demonstrated high efficacy for both formulations. Participants reported satisfactory erection hardness in 70% of encounters with Eroxon and 71% with Intense, while erections lasted long enough for intercourse in 84% and 85% of cases, respectively. Both products delivered clinically significant improvements in erectile function, consistent with prior Phase 3 data.

Eroxon Intense showed a statistically significant increase in sensorial effect compared to the standard formulation, particularly within the first two minutes of application. Both treatments were well tolerated by users and their partners, with improved outcomes observed when applied by partners, indicating enhanced effectiveness during shared use.

User satisfaction remained strong, with 49% and 53% of participants awarding 4- or 5-star ratings to Eroxon and Intense, respectively, and more than half indicating a likelihood to purchase. The findings support a targeted commercial strategy focused on men under 60 with mild to moderate erectile dysfunction, with the Intense variant positioned for consumers seeking a faster or more pronounced effect.

Futura Medical has generated the data required for regulatory submissions for Eroxon Intense in the US and Europe, including a Special 510(k) filing with the US Food and Drug Administration. Regulatory approvals are anticipated in H1 2026.